Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Horwitz SM, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S.
Han JX, et al. Among authors: ku a.
Blood Adv. 2025 Feb 11;9(3):583-602. doi: 10.1182/bloodadvances.2024014674.
Blood Adv. 2025.
PMID: 39481087